(Total Views: 102)
Posted On: 01/30/2020 10:30:43 AM
Post# of 104529
$APRE News Article - Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation https://marketwirenews.com/news-releases/apre...04784.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
